Publication of manus
Publication of manuscript related to Phase II trial results for arimoclomol in patients with SOD1 ALS
24 janv. 2018 16h06 HE | ORPHAZYME A/S
Investor newsOrphazyme A/SNo. 01/2018                                                                                                                                                              ...
TMlogo.jpg
Q Therapeutics Announces Research Collaboration With REPROCELL
13 déc. 2017 07h00 HE | Q Therapeutics, Inc.
SALT LAKE CITY and YOKOHAMA, Japan, Dec. 13, 2017 (GLOBE NEWSWIRE) -- Q Therapeutics, Inc., a developer of clinical-stage cell therapies for central nervous system (CNS) disease and injury,...
Logo Resized for Globe Newswire2.jpg
Preclinical Data Supporting Wave Life Sciences ALS and FTD Programs Presented at 28th International Symposium on ALS/MND
11 déc. 2017 07h00 HE | Wave Life Sciences
CAMBRIDGE, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious,...
Voyager_Logos_Square_Logo_Light.png
Voyager Therapeutics Reports Second Quarter 2017 Financial Results and Corporate Highlights
08 août 2017 07h05 HE | Voyager Therapeutics
CAMBRIDGE, Mass., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe neurological...
Cytokinetics.png
Cytokinetics Announces Start of FORTITUDE-ALS, a Phase 2 Clinical Trial of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis
27 juil. 2017 07h30 HE | Cytokinetics, Inc
SOUTH SAN FRANCISCO, Calif., July 27, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced the start of FORTITUDE-ALS, Functional Outcomes in a Randomized Trial of...
LabCentral Accepting Applications for Second-Floor Expansion; Move-in Ready Lab & Office Space Slated for Completion by Summer’s End
20 juin 2017 09h00 HE | LabCentral
CAMBRIDGE, Mass. and SAN DIEGO, Calif., June 20, 2017 (GLOBE NEWSWIRE) -- LabCentral, Greater Boston’s premier coworking laboratory launchpad for high-potential life-science startups, announced that...
MDA Awards $300,000
MDA Awards $300,000 to Streamline Gathering of Data for ALS Research
15 juin 2017 16h24 HE | Muscular Dystrophy Association
Chicago, June 15, 2017 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association has announced the award of a clinical research network grant (CRNG) to Michael Benatar, M.D., Ph.D., at the University...
Cytokinetics.png
Cytokinetics and the ALS Association Renew Partnership to Advance the Fight Against ALS
03 mai 2017 16h00 HE | Cytokinetics, Inc
SOUTH SAN FRANCISCO, Calif., and WASHINGTON, May 03, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) and The ALS Association today announced the continuation of their partnership in the...
Cytokinetics.png
Cytokinetics Announces New Data Presented at the International Symposium on ALS/MND
09 déc. 2016 07h30 HE | Cytokinetics, Inc
Patient Baseline Characteristics from VITALITY-ALS Comparable to BENEFIT-ALS Physician Survey Shows Regional Variability in Use of Noninvasive Ventilation SOUTH SAN FRANCISCO, Calif., Dec. 09,...
Cytokinetics.png
Origent Data Sciences and Cytokinetics Present Analyses Demonstrating Baseline Data Predict Measures of Vital Capacity in Patients With ALS
07 déc. 2016 07h30 HE | Cytokinetics, Inc
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2016 (GLOBE NEWSWIRE) -- Origent Data Sciences, Inc. (Origent) and Cytokinetics, Inc. (Nasdaq:CYTK) today announced results from the first part of a research...